GET DAILY SIGNALSALXO vs AXON: Biotech Catalyst Risk Against a De-Rated Growth Stock Down Over 50% from Peak
Key Takeaways
- ALXO is a clinical-stage, pre-revenue immuno-oncology biotech, while AXON is a profitable, fast-growing public-safety technology company — a stark contrast in business maturity and risk profile.
- Axon generates strong recurring revenue, with annual recurring revenue (ARR) up 39% to roughly $1.6 billion, while ALX Oncology reports no product revenue and relies on cash runway and clinical catalysts.
- AXON has been repriced sharply lower in recent months — down more than 50% from its 2025 peak — despite continued revenue growth, while ALXO trades near multi-year lows with a small market capitalization.
- ALXO's valuation hinges on binary clinical-trial outcomes for its lead drug evorpacept, whereas AXON's story centers on execution, margin compression, and valuation reset in a premium-growth stock.
- Analyst consensus is "Strong Buy" for ALXO and "Buy" for AXON, though the two ratings reflect very different underlying risk and reward frameworks.
- Investors can track more details on ALXO Major News and ALXO Today's Price Move, as well as AXON Major News and AXON Today's Price Move, for timely updates on each name.
- For automated, data-driven market analysis, explore Trending AI Robots to see which strategies are currently favored by AI trading systems.
Setting the Stage
Comparing ALXO (ALX Oncology Holdings) and AXON (Axon Enterprise) is, in many ways, a study in opposites. One is a small, clinical-stage biotechnology company with no product revenue whose fortunes depend on drug-trial data; the other is a multi-billion-dollar, revenue-generating leader in public-safety technology and software. This stock comparison is most relevant for investors weighing high-risk, catalyst-driven biotech exposure against a growth company undergoing a valuation reset. Both names have experienced meaningful volatility in recent market activity, making their relative performance and market positioning a useful lens for traders and longer-term investors alike. I also checked this using Tickeron’s AI Screener to see how the two names stack up against peers.
ALXO Overview and Recent Performance
ALX Oncology Holdings is a clinical-stage immuno-oncology company focused on therapies for cancer patients. Its lead candidate, evorpacept, is a CD47-blocking therapeutic (a drug that blocks a "don't eat me" signal used by cancer cells to evade the immune system), and it is being studied in combination with other anti-cancer agents across multiple tumor types. A second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate (ADC), a therapy that delivers a toxic payload directly to cancer cells.
In recent weeks, sentiment around ALXO has been shaped primarily by clinical data. Management presented results showing that evorpacept combined with zanidatamab produced durable responses in heavily pre-treated HER2-positive breast cancer patients, particularly those with high CD47 expression. The company has also received FDA Fast Track designations (a designation that can accelerate drug review) for evorpacept in certain indications. Despite these signals, the stock trades near its 52-week lows with a market capitalization well under $200 million, reflecting both the company's pre-revenue status and the binary risk inherent in clinical-stage biotech. Analyst consensus remains "Strong Buy," but the path to value realization depends heavily on upcoming trial readouts and regulatory progress.
AXON Overview and Recent Performance
Axon Enterprise is a public-safety technology company best known for its TASER conducted electrical weapons and body cameras, alongside a growing software and AI platform that includes evidence management, records tools, and counter-drone (Dedrone) capabilities. The company has evolved from a hardware maker into a recurring-software business, with annual recurring revenue (ARR) up 39% to about $1.6 billion and net revenue retention near 126%.
Recent market activity for AXON has been volatile. The shares have declined more than 50% from their 2025 peak and are down roughly 25% year-to-date, even as the company reported quarterly revenue of approximately $904 million (up about 35% year over year) and raised its full-year outlook. A five-day winning streak in late October, tied partly to the unveiling of the Axon Body 5 camera, trimmed some losses. Weighing on sentiment have been concerns about margin compression, a $1 billion convertible-note offering, and the premium valuation that the stock carried at its highs. Consensus is a "Buy" with an average price target well above the current price. From what I see, the recent pullback has created an interesting setup worth monitoring closely.
Head-to-Head Comparison
The contrasts between these two companies are fundamental. ALXO operates in biotechnology with a concentrated, binary risk profile: its near-term value is tied almost entirely to evorpacept's clinical outcomes and the company's cash runway, which funds operations without product revenue. Its sector exposure is to oncology drug development, where catalysts such as trial data and FDA decisions drive sharp, event-based price moves.
AXON, by contrast, has a diversified hardware-plus-software model with proven, growing revenue and a strong balance-sheet trajectory. Its growth drivers include AI adoption in public-safety workflows, international expansion, and newer categories like counter-drone technology. Its risks are more execution- and valuation-related: government budget dependence, margin compression during an investment cycle, and the challenge of sustaining premium growth rates. In terms of momentum, AXON has recently shown short-term stabilization after a prolonged drawdown, while ALXO remains in a lower-volatility but fundamentally speculative trading range. For a stock comparison, the trade-off is essentially between a catalyst-driven, high-upside micro-cap and a de-rated but fundamentally profitable growth company.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AXON for trend consistency and stability, given its established revenue base, recurring-software model, and emerging short-term momentum after a deep correction. ALXO's profile is more speculative, with value tied to binary clinical catalysts that AI models typically assess as higher-uncertainty. That said, ALXO's recent positive biomarker data and "Strong Buy" analyst consensus suggest meaningful upside potential if clinical milestones are met. The probabilistic view, therefore, leans toward AXON for relative stability and demonstrated fundamentals, while acknowledging ALXO as a higher-risk, higher-reward candidate whose outcome depends on trial results. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge longer-term signals.
Exploring AI Trading Strategies
In my own work, I regularly look at Tickeron’s AI Trading Bots to understand how different automated approaches are performing across market regimes. These tools let me compare strategies side by side without having to build everything from scratch, which helps keep the analysis grounded in current data rather than just narrative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXON's RSI Oscillator recovers from oversold territory
The RSI Indicator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 63 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.
Following a +2.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.415) is normal, around the industry mean (4.846). AXON has a moderately high P/E Ratio (172.417) as compared to the industry average of (16.894). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement